In plain language
In 268 coronary angiography and percutaneous coronary intervention (PCI) patients, a lab fitted with a new dose reduction technology recorded 34-46% lower patient dose-area product than a lab without it. Staff dose was not measured.
At a glance
- Type of study
- Original research, Prospective cohort study
- Who was studied
- Patients
- Size
- n = 268 patients
- Summary based on
- the abstract
What it found
For diagnostic coronary angiography, median total dose-area product was lower in the lab with the dose reduction technology than in the lab without it.
Key figures: 46% reduction (P < 0.0001)
For PCI, median total dose-area product was also lower in the lab with the technology.
Key figures: 34% reduction (P = 0.015)
Fluoroscopy time, number of images, contrast use and body mass index (BMI) did not differ between labs, suggesting comparable procedures.
Key figures: fluoroscopy time P = 1 (diagnostic), P = 0.765 (interventional)
Limits to keep in mind
Non-randomized comparison of two different labs with consecutive patients, so lab, operator and equipment differences may confound results; only patient dose-area product (DAP) was measured, with no staff dose data, and the technology is not described in the abstract.
Related research summaries
- Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry (2026, Prospective cohort study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
- Utilization of a Radiation Safety Time-Out Reduces Radiation Exposure During Electrophysiology Procedures (2019, Prospective cohort study)
- Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia (2018, Case report or series)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.